News


202021AUG

Call for Feasibility Studies

Closing date for expression of interests: 16th September 2020
Closing date for applications: 1st October 2020
 
The EPSRC Future Manufacturing CMAC Research Hub is offering funding to support four Feasibility Studies at TRLs 1 – 4.

The funding is available for novel short-term research studies of advanced manufacturing technologies to complement the current Hub research programme of advanced pharmaceutical manufacturing.

This call seeks to support studies primarily aligned with innovative approaches to digital design and application of advanced measurements.

The call is open to all UK academics eligible to receive EPSRC funding and is the primary mechanism for new academic collaborators to engage with the Hub. Awards are limited to a maximum of £60k at 80% FEC and for a project duration of 6-12 months. This call seeks to stimulate applications from existing groups where there is opportunity to leverage significant existing activity that would lead to an ongoing collaboration following feasibility studies. To facilitate active collaboration a Hub Champion will be assigned to work with each funded proposal.

Scope of the Call
Feasibility call proposals will be complementary to overall research scope and Hub vision and establish new activity in the areas of:
• Innovative approaches to digital design to continuous processes or pharmaceutical products
• Application of advanced measurement to understand material of formulated systems
• Potential application of continuous technologies beyond small molecule pharmaceuticals

Funding Available
The maximum funding available for each funded project is £60k for a duration of up to 6 months. Where feasible applicants are encouraged to propose a co-funding model to extend project duration up to a maximum of 12 months. The £60k represents 80% of the Full Economic Cost (FEC). Institutions are requested to itemise bills based on 100% FEC and then invoice at 80% FEC.

Eligibility
This call is open to all UK academic institutions (including existing Hub and Spoke institutions), where applicants must be eligible to hold an EPSRC grant. If you need guidance on eligibility, please visit https://epsrc.ukri.org/funding/applicationprocess/fundingguide/eligibility/investigators/ 

How to apply
Prior to submitting a written application please contact Hub Programme Manager, Dr Andrea Johnston (andrea.johnston@strath.ac.uk) to express interest. Expression of interest should be no more than 1 page of A4 submitted by email outlining research area and track record of applicants.

Applicants will be notified by Friday 18th September if they should submit an application.

202023JUL

Business Case Insights for Continuous Manufacturing

CMAC and PwC are delighted to share ‘The Business Case Insights for Continuous Manufacturing’. This joint document, with input from industrial partners, seeks to review key considerations for building a successful business case for the industrial adoption of innovative Continuous Manufacturing (CM) technologies.

The report is written from the perspective of the CMAC manufacturing research programme stakeholders. Hence, it targets factors directly relevant to continuous small molecule pharmaceutical manufacture and although addresses the many drivers and impacts across the entire value chain, brings a strong emphasis on factors relevant to continuous drug substance manufacture.

With the associated growth in new technologies and services comes the opportunity for different business models that exploit CM to deliver additional value and tackle major challenges facing the sector: how are we to manage spiralling prescription medicine costs in the NHS and other global healthcare systems; can the pharmaceutical supply chain deliver greater personalisation of medicines quickly and cost effectively; can the security of global medicines supply be assured to maintain access to essential medicines or respond to medical emergencies; how can the impact of medicines manufacture on the environment be minimised and made more sustainable? Those that can best harness the potential of innovative technologies such as CM will be best placed to meet these challenges.

Nine critical considerations have been highlighted for business case development. Through each of these lenses, a holistic case for continuous manufacturing can be progressed to help drive the uptake of this currently novel technology.


Please view full document here


This document was undertaken with engagement from CMAC Tier 1 partners AstraZeneca, Eli Lilly, Pfizer and Takeda as well as leveraging CMAC’s own extensive academic portfolio on end-to-end (E2E) processing. CMAC would like to thank all those who have contributed information and viewpoints on key technical aspects in combination with PwC’s wider business case perspective, to help inform and engage senior stakeholders and drive continuous manufacturing forward.

202001JUN

CPI launches the SCOUT project to benefit chemical and biochemical SMEs across Scotland

CPI, an independent technology innovation centre and founding member of the UK Government’s High Value Manufacturing Catapult, has today announced the launch of SCOUT, a project to target a breadth of Scottish SMEs working in the high value chemical and biochemical supply chains. The project will leverage technology within CPI and its partner organisations to accelerate and de-risk the growth of Scottish SMEs – including those underserved and remote – by enabling new partnerships and increased technology adoption.

The SCOUT project, which will run over the next three years, will be led by CPI’s Medicines Manufacturing Innovation Centre and is being launched in collaboration with CMAC Future Manufacturing Research Hub and the Industrial Biotechnology Innovation Centre (IBioIC). It aims to serve Scottish SMEs through a three-pronged approach of innovation clinics (currently planned to start in late 2020), Innovation Integrator assessments and deep technical consultancy. The £882k Scottish Outreach (SCOUT) project is jointly funded by the European Regional Development Fund (managed by Scottish Enterprise) CPI, CMAC and IBioIC.

Fifty SMEs from across Scotland will be selected to attend the planned innovation clinics, supported by all of the partner organisations. Companies will be connected to new networks and supply chains in order to encourage partnerships and attend workshops with a focus on common technology and business challenges, including equality, sustainability and diversity. As location can often act as a barrier to event attendance, two innovation clinics will be located in central Scotland, while the other two will be located in the Highlands & Islands region.

CPI will also provide promising SMEs with Innovation Integrator assessments, a proprietary diagnostic tool used to identify innovation gaps, prioritise resources, and both assess and improve the market readiness of a product or process. Finally, deep technical consultancy – supported by all project partners – will provide selected SMEs with the opportunity to receive knowledge and expertise on specific topics, as well as providing the next steps for implementing specific recommendations.

The SCOUT project aims to drive future economic growth in Scotland, providing services for underserved Scottish SMEs and ensuring previous barriers – as a result of geographical or technical limitations – are removed. This connection and support will ultimately generate new ideas and revenue, helping to accelerate the delivery of disruptive technology to the market.

Professor Alastair Florence, Director, CMAC Future Manufacturing Research Hub, said: “This is an exciting opportunity for the Scottish research, innovation and SME community to stand out. Access to innovation clinics and consultancy, supporting all of Scotland, will allow new and unique services and products to enter the market and support economic growth at a time when this is more important than ever. This inventive, collaborative approach  would not have been possible without the SCOUT project. The CMAC Future Manufacturing Research Hub works in partnership with industry and the supply chain to transform medicines development and manufacture.”

Dr Mark Bustard, CEO, IBioIC, said: “IBioIC is delighted to work with CPI on the SCOUT project. Alongside CMAC, IBioIC will support our industry members and Scotland’s wider Industrial Biotechnology community to ensure that the SMEs can take advantage of the tools created through the SCOUT project to accelerate the exploitation of their innovations.”

Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre at CPI, said: “The SCOUT project is providing Scottish SMEs in the high value chemical and biochemical supply chains with a great opportunity to drive forward the Scottish economy once the COVID-19 pandemic is over”.


Notes to the Editor

About CPI

CPI is an independent technology innovation centre and a founding member of the UK Government’s High Value Manufacturing Catapult. Founded in 2004, CPI applies its years of experience across a broad range of industries to ensure that every great invention gets the best opportunity to become a successfully marketed product.

CPI’s integrated approach provides its partners with a unique combination of assets, expertise and skills to drive successful innovation. With a deep understanding of innovation processes and funding, outstanding technical expertise and industry-relevant assets, CPI enables products and processes to be quickly and cost-effectively brought to market. By employing bright minds from both academia and industry, CPI helps create a bespoke team that will provide the right support, helping you to navigate the route to commercialisation while reducing risk along the way.

We form connections throughout the supply chain, bringing together investors, government organisations and academic institutions to facilitate the necessary partnerships for effective innovation. This increases productivity across industries and supports the development of next-generation manufacturing, highly-skilled jobs and economic growth for the UK.

www.uk-cpi.com

About CMAC

EPSRC CMAC Future Manufacturing Hub is an international hub of excellence for medicines manufacturing research, led from the University of Strathclyde, comprises academic investigators and research staff across 7 leading universities.  Our vision is to lead the world in advanced pharmaceutical manufacturing underpinned by our MicroFactory and digitalisation strategy. Established in 2011, CMAC’s vision has been developed through close collaboration with industry and the support of its Tier 1 partners: AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Roche and Takeda. Working in partnership with industry, its purpose is to transform current manufacturing processes into the medicine supply chain of the future.

For more information visit www.cmac.ac.uk

About the Industrial Biotechnology Innovation Centre (IBioIC)

The Industrial Biotechnology Innovation Centre (IBioIC) is a networking and support organisation that connects industry, academia and government to bring biotechnology processes and products to the global market. It does this by offering scale-up facilities, talent development, funding provision, and promotion of Scotland’s unique assets.

IBioIC was established in 2014 to fulfil the aims of the National Plan for Industrial Biotechnology to grow a £900m biotechnology industry in Scotland by 2025. Biotechnology uses plant-based and waste resources to produce or process materials, chemicals and energy, offering green and sustainable alternatives to fossil fuels in everything from energy to medicines to food packaging.

IBioIC supports over 130 companies, 50 research projects, and works with 18 Scottish universities and research institutes. IBioIC is hosted by the University of Strathclyde in Glasgow’s Innovation District.

www.IBioIC.com
@IBioIC

Advancing Manufacturing Challenge Fund

The Advancing Manufacturing Challenge Fund is a partnership between the Scottish Government, Scottish Enterprise, and Highlands and Islands Enterprise. A full list of successful projects is available on the AMCF website. Total investment is £15.8 million, with £8.3 million from the European Regional Development Fund, £590,000 from the Scottish Government, and the remainder in match-funding from the chosen projects. 

The Scottish Government is the Managing Authority for the European Structural Funds 2014-20 Programme. For further information visit our webpages or follow @scotgovESIF.

 


202019MAR

CMAC Future Manufacturing Research Hub Operations during COVID-19

In response to the Covid-19 outbreak and following advice from the WHO, the UK and Scottish Governments, the University of Strathclyde has taken the decision to restrict highly populated areas in the interest of student and staff safety.  Therefore CMAC has closed all laboratory and office areas.​

As we anticipated this would be a possible course of action, we have been able to minimize the disruption and impact to active projects.  Our staff will be working remotely, and you will be contacted by the project lead, project manager or business development manager to advise you on your specific project and the impact to project timelines.​

In planning for the potential impact of the evolving coronavirus situation, the safety, health and wellbeing of the staff and students is our priority.  Thank you for your understanding.​

We will be keeping our partners and collaborators updated via our website and social media channels (Twitter, LinkedIn & YouTube).


CMAC Team

info@cmac.ac.uk


202003FEB

New Industry Director joins CMAC

We are delighted to announce the appointment of Massimo Bresciani as CMAC’s new Industry Director from the 3rd February 2020. As Industry Director, Massimo will provide leadership to CMAC’s industry engagement, knowledge exchange and research translation activities for our industry and academic partners across major programs including the EPSRC Future Manufacturing Research Hub. Massimo has gathered a wealth of experience from his career, spanning many years in industry and most recently working in a senior role at the academic-industry interface. 

“I am delighted to welcome Massimo to join CMAC and look forward to working with him to deliver the next phase of our growth as a global research hub for advanced pharmaceutical manufacturing research and skills development.” said Alastair Florence, CMAC Director

Dr Jon-Paul Sherlock, CMAC Industry Board Chair said “The translation of the excellent research at CMAC into industrial impact is a priority for the Industry Board.  I look forward to working with Massimo, to build on what is already a strength for CMAC, to deliver new approaches that accelerate translation and maximise value for partners.”

Speaking about his appointment Massimo stated “It is an honour to be joining CMAC’s leadership team and offer my experience and drive to deliver the impact from its innovative and disruptive programmes.  I am really excited about this new opportunity to deliver value for our partners and look forward to taking up the role."

Please view full announment on University of Strathclyde website

Massimo Bresciani joins CMAC as Industry Director


201921OCT

MMIC to Develop Platform for Quicker Optimization of OSD Formulations

"MMIC to Develop Platform for Quicker Optimization of OSD Formulations"  21/10/2019, Contract Pharma. Link to article.

Partnership between CPI, University of Strathclyde, GSK and AstraZeneca to utilize continuous manufacturing process. MMIC Grand Challenge 1 underway with CMAC at University of Strathclyde.

News

Call for Feasibility Studies
Closing date for expression of interests: 1st October 2020

Closing date for applications: 16th October 2020



The EPSRC Future Manufacturing CMAC Research Hub is offering funding to support four Feasibility Studies at TRLs 1 – 4.



The funding is available for novel short-term research studies of advanced manufacturing technologies to complement the current Hub research programme of advanced pharmaceutical manufacturing.



This call seeks to support studies primarily aligned with innovative approaches to digital design and application of advanced measurements.



The call is open to all UK academics eligible to receive EPSRC funding and is the primary mechanism for new academic collaborators to engage with the Hub. Awards are limited to a maximum of £60k at 80% FEC and for a project duration of 6-12 months. This call seeks to stimulate applications from existing groups where there is opportunity to leverage significant existing activity that would lead to an ongoing collaboration following feasibility studies. To facilitate active collaboration a Hub Champion will be assigned to work with each funded proposal..... more

Business Case Insights for Continuous Manufacturing
CMAC and PwC are delighted to share ‘The Business Case Insights for Continuous Manufacturing’. This joint document, with input from industrial partners, seeks to review key considerations for building a successful business case for the industrial adoption of innovative Continuous Manufacturing (CM) technologies..... more